Search
Bopindolol
go.drugbank.com/drugs/DB08807ExperimentalBopindolol (INN) is an ester prodrug for the beta blocker [pindolol].
Befunolol
go.drugbank.com/drugs/DB09013ExperimentalBefunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
Avdoralimab
go.drugbank.com/drugs/DB16392InvestigationalAvdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
Sulfamoxole
go.drugbank.com/drugs/DB08798ExperimentalSulfamoxole is an antibacterial in the sulfonamide class.
Synonyms: N(sup 1)-(4,5-Dimethyl-2-oxazolyl)sulfanilamide, 4-Amino-N-(4,5-dimethyl-2-oxazolyl)benzenesulfonamideMethaqualone
go.drugbank.com/drugs/DB04833ApprovedIllicitWithdrawnThe sedative-hypnotic activity was first noted by Indian researchers in the 1950s and in 1962 methaqualone itself was patented in the US by Wallace and Tiernan. … It has also been used illegally as a recreational drug, commonly known as Quaaludes, Sopors, Ludes or Mandrax (particularly in the 1970s in North America) depending on the manufacturer.
Carmegliptin
go.drugbank.com/drugs/DB12268InvestigationalCarmegliptin has been used in trials studying the treatment of Diabetes Mellitus Type 2.
Categories: DPP-IV InhibitorsVercirnon
go.drugbank.com/drugs/DB15250InvestigationalIt is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786). … Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD.
International brands: Traficet-ENCanfosfamide
go.drugbank.com/drugs/DB04972InvestigationalCanfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
Snail, unspecified
go.drugbank.com/drugs/DB14245ApprovedInvestigationalSnail, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
ATG003
go.drugbank.com/drugs/DB05069InvestigationalATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.